Skip to Main content Skip to Navigation
Journal articles

Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis

M. Bashashati 1 S. Moossavi 2 C. Cremon 3 M. Barbaro 3 S. Moraveji 4 G. Talmon 5 N. Rezaei 2 P. Hughes 6 Z. Bian 7 C. Choi 8 O. Lee 9 M. Coëffier 10, 11, 12, 13 L. Chang 14 L. Ohman 15 M. Schmulson 16 R. Mccallum 4 M. Simren 15 K. Sharkey 17 G. Barbara 3
1 TTU - Texas Tech University [Lubbock]
2 TUMS - Tehran University of Medical Sciences
3 University of Bologna
4 Texas Tech University Health Sciences Center
5 University of Nebraska Medical Center
6 University of Adelaide
7 HKBU - Hong Kong Baptist University
8 Chung-Ang University [Seoul]
9 Hanyang University
10 ADEN - Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau
11 IRIB - Institute for Research and Innovation in Biomedicine
12 Service de nutrition [CHU Rouen]
13 UNIROUEN UFR Santé - UNIROUEN - UFR Santé
14 David Geffen School of Medicine [Los Angeles]
15 Sahlgrenska Academy at University of Gothenburg [Göteborg]
16 UNAM - Universidad Nacional Autónoma de México
17 University of Calgary
Abstract : Background & Aims Increases in mucosal immune cells have frequently been observed in irritable bowel syndrome (IBS) patients. However, this finding is not completely consistent between studies, possibly due to a combination of methodological variability, population differences and small sample sizes. We performed a meta‐analysis of case–control studies that compared immune cell counts in colonic biopsies of IBS patients and controls. Methods PubMed and Embase were searched in February 2017. Results were pooled using standardized mean difference (SMD) and were considered significant when zero was not within the 95% confidence interval (CI). Heterogeneity was assessed based on I2 statistics where I2 ≤ 50% and I2 > 50% indicated fixed and random effect models, respectively. Key Results Twenty‐two studies on 706 IBS patients and 401 controls were included. Mast cells were increased in the rectosigmoid (SMD: 0.38 [95% CI: 0.06‐0.71]; P = .02) and descending colon (SMD: 1.69 [95% CI: 0.65‐2.73]; P = .001) of IBS patients. Increased mast cells were observed in both constipation (IBS‐C) and diarrhea predominant IBS (IBS‐D). CD3+ T cells were increased in the rectosigmoid (SMD: 0.53 [95% CI: 0.21‐0.85]; P = .001) and the descending colon of the IBS patients (SMD: 0.79, 95% CI [0.28‐1.30]; P = .002). This was possibly in relation to higher CD4+ T cells in IBS (SMD: 0.33 [95% CI: 0.01‐0.65]; P = .04) as there were no differences in CD8+ T cells. Conclusions & Inferences. Mast cells and CD3+ T cells are increased in colonic biopsies of patients with IBS vs non‐inflamed controls. These changes are segmental and sometimes IBS‐subtype dependent. The diagnostic value of the quantification of colonic mucosal cells in IBS requires further investigation.
Document type :
Journal articles
Complete list of metadatas
https://hal-normandie-univ.archives-ouvertes.fr/hal-02315165
Contributor : Sabine Douville <>
Submitted on : Monday, October 14, 2019 - 12:05:55 PM
Last modification on : Thursday, July 2, 2020 - 3:42:27 AM

Identifiers

Collections

COMUE-NORMANDIE | ADEN | UNIROUEN | CNRS

Citation

M. Bashashati, S. Moossavi, C. Cremon, M. Barbaro, S. Moraveji, et al.. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterology & Motility, 2018, 30 (1), pp.e13192. ⟨10.1111/nmo.13192⟩. ⟨hal-02315165⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

35